Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

Profil Institut für Stoffwechselforschung

Status and phase: Completed; Phase 2

Conditions: Diabetes Mellitus

Treatments: Drug: Luyxumia versus Lantus

Study type: Interventional

Funder types: Industry

Identifiers

NCT01910194

LanLyx

Details and patient eligibility

About

Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying

Full description

Impact of combined Lantus (insulin glargine) and Lyxumia(lixisenatide) on insulin secretion and gastric emptying

Enrollment: 39 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with type 2 diabetes mellitus diagnosed at least one year before the screening visit not previously treated with glitazones, insulin or GLP-1 agonists
• Inadequately controlled diabetes mellitus

Exclusion criteria

• Subjects with type 1 diabetes, maturity onset diabetes of the young (MODY) or secondary forms of diabetes such as due to pancreatitis

Trial design

39 participants in 2 patient groups

Lyxumia

Other group

Description:

4 weeks Luxumia plus another 4 weeks combination

Treatment:

Drug: Luyxumia versus Lantus

Lantus

Other group

Description:

4 weeks Lantus plus another 4 weeks combination

Treatment:

Drug: Luyxumia versus Lantus